Table 2. Associations of MAC clinicopathologic and molecular characteristics with cancer relapse.
Characteristic | Stage I to III | Stage III | ||||
---|---|---|---|---|---|---|
No. of patientsa | Relapse-free survival (%) | P Value | No. of patientsb | Relapse-free survival (%) | P-value | |
Gender | 0.605 | 0.255 | ||||
Female | 29 | 75.9 | 17 | 70.6 | ||
Male | 31 | 67.7 | 12 | 41.7 | ||
Age | 0.172 | 0.335 | ||||
≤ 70 years | 33 | 63.6 | 18 | 50 | ||
> 70 years | 27 | 81.5 | 11 | 72.7 | ||
Location | 0.001 | < 0.001 | ||||
Proximal colon | 33 | 90.9 | 13 | 100 | ||
Distal colon or rectum | 27 | 48.1 | 16 | 25 | ||
Differentiation | 0.78 | 0.307 | ||||
Well | 10 | 80 | 5 | 80 | ||
Moderate | 43 | 69.8 | 19 | 47.4 | ||
Poor | 7 | 71.4 | 5 | 80 | ||
pT status | 0.225 | 0.043 | ||||
pT1 or pT2 or pT3 | 51 | 74.5 | 26 | 65.4 | ||
pT4 | 9 | 55.6 | 3 | 0 | ||
pN status | 0.091 | 0.578 | ||||
pN0 | 31 | 83.9 | - | - | ||
pN1 | 20 | 60 | 20 | 60 | ||
pN2 | 9 | 55.6 | 9 | 55.6 | ||
AJCC TNM stage | 0.035 | - | - | - | ||
Stage I or II | 31 | 83.9 | ||||
Stage III | 29 | 58.6 | ||||
SAC morphology | (n=56) | 0.144 | (n=27) | 0.035 | ||
Absent | 34 | 67.6 | 17 | 47.1 | ||
Present | 22 | 86.4 | 10 | 90 | ||
CIMP status | (n=56) | 0.091 | (n=26) | 0.009 | ||
Negative | 44 | 63.6 | 18 | 33.3 | ||
Positive | 12 | 91.7 | 8 | 100 | ||
SAC morphology and CIMP-positive status | (n=54) | 0.035 | (n=25) | 0.005 | ||
Presence of both or either one | 26 | 88.5 | 12 | 91.7 | ||
Absence of both | 28 | 60.7 | 13 | 30.8 | 0.488 | |
KRAS status | (n=55) | 0.467 | (n=28) | |||
Wild type | 33 | 72.7 | 16 | 62.5 | ||
Mutant | 22 | 63.6 | 12 | 50 | ||
BRAF status | (n=55) | 0.643 | (n=28) | 0.214 | ||
Wild type | 46 | 69.6 | 22 | 50 | ||
Mutant | 9 | 77.8 | 6 | 83.3 | ||
MMR status | 0.093 | 0.241 | ||||
Proficient | 44 | 65.9 | 21 | 52.4 | ||
Defective | 16 | 87.5 | 8 | 75 |
AJCC, American Joint Committee on Cancer; CIMP, CpG island methylator phenotype; MAC, mucinous adenocarcinoma; MMR, DNA mismatch repair; HR, hazard ratio; SAC, serrated adenocarcinoma.
a Values are calculated for 60 patients unless specified otherwise.
b Values are calculated for 29 patients unless specified otherwise.